Follicular Challenge Test to Predict Response to GnRH Agonist Triggering

Infertility, Female Clinical Trial

Official title:

Follicular Challenge Test to Predict Response to GnRH Agonist Triggering

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04973969
• Other study ID #: 0304-20-ASF
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2021
• Est. completion date: April 30, 2022

Study information

• Verified date: July 2021
• Source: Assaf-Harofeh Medical Center
• Contact: Sarit Avraham, Dr
• Phone: 00972522371126
• Email: sarita[@]shamir.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or suboptimal response was displayed.

The investigators aim to asses the possibility to predict the respone to ovulation triggering by the response to decapeptyl in the follicular phase of the same cycle.

Description:

The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist protocol.

Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the hormonal profile will be compared to day after ovulation triggering.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: April 30, 2022
• Est. primary completion date: April 30, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 41 Years

Eligibility

Inclusion Criteria:

• patients that undergo fertility preservation

• patients planned to freeze embryos due to PGT or surrogacy --patients at high risk for OHSS

Exclusion Criteria:

• Poor ovarian response

• known hypothalamic- pituitary dysfunction

Related Conditions & MeSH terms

• Infertility
• Infertility, Female

Intervention

Other:
• Decapeptyl
diagnosis of predictio value

Locations

Country	Name	City	State
Israel	Shamir medical center	Tzrifin

Sponsors (1)

Lead Sponsor	Collaborator
Assaf-Harofeh Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The response to GnRH triggering	LH levels 10-12 hours after decapeptyl trigger, number of mature oocytes	One treatment cycle (each cycle is 28 days) for each participant (up to 28 days).